These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 31146971

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L, Tanaka T, Saito H, Sugahara M, Wakashima T, Fukui K, Nangaku M.
    Am J Physiol Renal Physiol; 2020 Feb 01; 318(2):F388-F401. PubMed ID: 31841388
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
    Tanaka T, Eckardt KU.
    Semin Nephrol; 2018 May 01; 38(3):267-276. PubMed ID: 29753402
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [HIF-ɑ: New Target For Treatment of Renal Anemia. Molecular Aspects and Activation of Pathway HREs].
    Mazza F, Cicciarelli A, Rubino F, Apponi F, Cioffi EA, Simonelli R.
    G Ital Nefrol; 2024 Jun 28; 41(3):. PubMed ID: 38943324
    [Abstract] [Full Text] [Related]

  • 15. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult.
    Vogler M, Zieseniss A, Hesse AR, Levent E, Tiburcy M, Heinze E, Burzlaff N, Schley G, Eckardt KU, Willam C, Katschinski DM.
    Pflugers Arch; 2015 Oct 28; 467(10):2141-9. PubMed ID: 25578858
    [Abstract] [Full Text] [Related]

  • 16. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K, Li Z, Yu Y, Zhang X.
    Drug Discov Today; 2020 Jul 28; 25(7):1262-1269. PubMed ID: 32380083
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
    Zhou J, Li J, Rosenbaum DM, Zhuang J, Poon C, Qin P, Rivera K, Lepore J, Willette RN, Hu E, Barone FC.
    PLoS One; 2017 Jul 28; 12(9):e0184049. PubMed ID: 28880966
    [Abstract] [Full Text] [Related]

  • 19. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
    Su X, Xie Y, Zhang J, Li M, Zhang Q, Jin G, Liu F.
    Cell Death Dis; 2022 Oct 08; 13(10):861. PubMed ID: 36209275
    [Abstract] [Full Text] [Related]

  • 20. Contribution of TFEB-mediated autophagy to tubulointerstitial fibrosis in mice with adenine-induced chronic kidney disease.
    Yuan H, Zheng C, Zhu L, Song Z, Dai L, Hu Q, Wang L, Chen Y, Xiong J.
    Biomed Pharmacother; 2021 Jan 08; 133():110949. PubMed ID: 33227703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.